AU2021381664B2 - Triazine dione derivative, preparation method therefor and application thereof in medicine - Google Patents

Triazine dione derivative, preparation method therefor and application thereof in medicine

Info

Publication number
AU2021381664B2
AU2021381664B2 AU2021381664A AU2021381664A AU2021381664B2 AU 2021381664 B2 AU2021381664 B2 AU 2021381664B2 AU 2021381664 A AU2021381664 A AU 2021381664A AU 2021381664 A AU2021381664 A AU 2021381664A AU 2021381664 B2 AU2021381664 B2 AU 2021381664B2
Authority
AU
Australia
Prior art keywords
membered
general formula
compound
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021381664A
Other languages
English (en)
Other versions
AU2021381664A1 (en
AU2021381664A9 (en
Inventor
Hongbo Fei
Feng He
Weimin Hu
Weikang Tao
Xiaomin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Pharmaceutical Co Ltd
Publication of AU2021381664A1 publication Critical patent/AU2021381664A1/en
Publication of AU2021381664A9 publication Critical patent/AU2021381664A9/en
Assigned to JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. reassignment JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. Request for Assignment Assignors: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
Application granted granted Critical
Publication of AU2021381664B2 publication Critical patent/AU2021381664B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021381664A 2020-11-20 2021-11-19 Triazine dione derivative, preparation method therefor and application thereof in medicine Active AU2021381664B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202011310827 2020-11-20
CN202011310827.4 2020-11-20
CN202110021509.4 2021-01-08
CN202110021509 2021-01-08
CN202110244090 2021-03-05
CN202110244090.9 2021-03-05
CN202110464375 2021-04-28
CN202110464375.3 2021-04-28
PCT/CN2021/131642 WO2022105852A1 (zh) 2020-11-20 2021-11-19 三嗪二酮类衍生物、其制备方法及其在医药上的应用

Publications (3)

Publication Number Publication Date
AU2021381664A1 AU2021381664A1 (en) 2023-06-15
AU2021381664A9 AU2021381664A9 (en) 2024-10-03
AU2021381664B2 true AU2021381664B2 (en) 2026-05-28

Family

ID=81708401

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021381664A Active AU2021381664B2 (en) 2020-11-20 2021-11-19 Triazine dione derivative, preparation method therefor and application thereof in medicine

Country Status (10)

Country Link
US (1) US20240010639A1 (cg-RX-API-DMAC7.html)
EP (1) EP4249474A4 (cg-RX-API-DMAC7.html)
JP (2) JP7849587B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230110538A (cg-RX-API-DMAC7.html)
CN (4) CN119638681A (cg-RX-API-DMAC7.html)
AU (1) AU2021381664B2 (cg-RX-API-DMAC7.html)
CA (1) CA3198934A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005533A (cg-RX-API-DMAC7.html)
TW (1) TW202227420A (cg-RX-API-DMAC7.html)
WO (1) WO2022105852A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
IL325304A (en) * 2018-10-29 2026-02-01 Myokardia Inc 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
TW202302541A (zh) * 2021-03-17 2023-01-16 美商翰森生物有限責任公司 含氮雜環酮、其製備方法和醫藥用途
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
CN117088854A (zh) * 2022-05-20 2023-11-21 江苏恒瑞医药股份有限公司 一种三嗪二酮类衍生物的可药用盐、晶型及制备方法
WO2023222103A1 (zh) 2022-05-20 2023-11-23 江苏恒瑞医药股份有限公司 一种三嗪二酮类衍生物的晶型及制备方法
WO2024056096A1 (zh) * 2022-09-16 2024-03-21 江苏豪森药业集团有限公司 一种含氮杂环酮化合物的晶型及其制备方法
WO2026130464A1 (zh) * 2024-12-18 2026-06-25 江苏恒瑞医药股份有限公司 制备治疗肥厚型心肌病药物的用途
WO2026153470A1 (zh) * 2025-01-16 2026-07-23 江苏恒瑞医药股份有限公司 制备治疗非梗阻性肥厚型心肌病药物的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205223A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Pyrimidinedione compounds against cardiac conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5502089B2 (ja) * 2008-10-09 2014-05-28 エフ.ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
SG173647A1 (en) * 2009-02-13 2011-10-28 Shionogi & Co Novel triazine derivative and pharmaceutical composition containing same
US20110319400A1 (en) * 2010-06-28 2011-12-29 Flores Christopher M Prokineticin 1 receptor antagonists for the treatment of pain
US9718790B2 (en) * 2010-08-10 2017-08-01 Shionogi & Co., Ltd. Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US9663516B2 (en) * 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
IL322175A (en) 2017-08-04 2025-09-01 Myokardia Inc Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds
CN111094300B (zh) * 2018-01-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并杂芳基类衍生物、其制备方法及其在医药上的应用
MA53491A (fr) * 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
IL325304A (en) 2018-10-29 2026-02-01 Myokardia Inc 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione
WO2020151605A1 (zh) * 2019-01-25 2020-07-30 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途
CN110698415B (zh) 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
TW202302541A (zh) * 2021-03-17 2023-01-16 美商翰森生物有限責任公司 含氮雜環酮、其製備方法和醫藥用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205223A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Pyrimidinedione compounds against cardiac conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1391355-99-9; STN Entry Date 15 August 2012; 2-fluoro-α,5-dimethyl-Benzenemethanamine hydrochloride *

Also Published As

Publication number Publication date
CA3198934A1 (en) 2022-05-27
AU2021381664A1 (en) 2023-06-15
JP2023550444A (ja) 2023-12-01
KR20230110538A (ko) 2023-07-24
CN116323598B (zh) 2024-11-15
CN119638680A (zh) 2025-03-18
EP4249474A4 (en) 2024-04-17
CN119638682A (zh) 2025-03-18
EP4249474A1 (en) 2023-09-27
WO2022105852A1 (zh) 2022-05-27
CN116323598A (zh) 2023-06-23
US20240010639A1 (en) 2024-01-11
JP2026097848A (ja) 2026-06-16
JP7849587B2 (ja) 2026-04-22
TW202227420A (zh) 2022-07-16
MX2023005533A (es) 2023-05-25
CN119638681A (zh) 2025-03-18

Legal Events

Date Code Title Description
SREP Specification republished
PC1 Assignment before grant (sect. 113)

Owner name: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Free format text: FORMER APPLICANT(S): JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.; SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO GAIN ACCEPTANCE HAS BEEN EXTENDED TO 10 JUN 2026